Eli Lilly & CO Form 4 insider transactions

Mary Lynne Hedley, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan, with the shares to be settled after her separation from service.

Eli Lilly director Ralph Alvarez acquired 13 shares of common stock through a deferral plan, increasing his direct holdings to 54,254 shares.

Eli Lilly executive Daniel Skovronsky reported the transfer of company shares through gifts, including to a family trust and his spouse.

Lilly Endowment Inc. sold a total of 23,084 shares of Eli Lilly & Co common stock in multiple transactions on September 3, 2024.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., has sold a portion of its holdings in multiple transactions on August 27, 2024.

Donald A. Zakrowski, SVP, Finance, & CAO of Eli Lilly, sold 750 shares of common stock at $950 per share on August 26, 2024, under a pre-arranged 10b5-1 trading plan.

Lilly Endowment Inc. sold 3,196 shares of Eli Lilly & Co. common stock in multiple transactions on August 22, 2024.

Eli Lilly CEO David Ricks reported a transfer of shares and updated his beneficial ownership in a recent SEC filing.

Gabrielle Sulzberger, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Director Kimberly H. Johnson acquired 10 shares of Eli Lilly stock through a deferral plan, with settlement occurring after her service ends.

Mary Lynne Hedley, a director at Eli Lilly, acquired 11 shares of common stock through a deferral plan, with existing holdings of 1,524 shares held indirectly through a trust.

Eli Lilly director Ralph Alvarez acquired 13 shares of common stock through a deferral plan, with settlement occurring after his separation from service.

An Eli Lilly executive, Anat Hakim, transferred 14,700 shares of company stock to a spousal lifetime access trust on August 12, 2024.

Melissa Seymour, an Executive Vice President at Eli Lilly, was granted 2,885 restricted stock units on August 1, 2024, which will vest over the next three years.

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 10 shares of common stock through a deferral plan.

Director Juan R. Luciano acquired 16 shares of Eli Lilly common stock at $950.46 per share through a deferral plan.

Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 10 shares of common stock through a deferral plan.

Mary Lynne Hedley, a director at Eli Lilly, acquired 10 shares of common stock through a deferral plan, while also holding 98 shares indirectly through a trust.

Director Ralph Alvarez acquired 12 shares of Eli Lilly common stock through a deferral plan, at a price of $950.46 per share.

Lilly Endowment Inc. sold over 190,000 shares of Eli Lilly & Co. stock in a series of transactions on July 10, 2024, at prices ranging from $936.50 to $945.25.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a substantial number of shares on July 8, 2024, at various prices.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on July 5, 2024.

Lilly Endowment Inc. sold 8,848 shares of Eli Lilly & Co. common stock in multiple transactions on July 3, 2024, at weighted average prices ranging from $915.144 to $917.726.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings on July 1, 2024.

Lilly Endowment Inc. sold 1,441 shares of Eli Lilly & Co. at a weighted average price of $915.021 per share on June 28, 2024.

Lilly Endowment Inc. sold a total of 187,106 shares of Eli Lilly & Co. common stock on June 25, 2024, at various weighted average prices.

Lilly Endowment Inc. sold 17,229 shares of Eli Lilly & Co. common stock in multiple transactions on June 24, 2024.

Lilly Endowment Inc. sold a total of 9,671 shares of Eli Lilly & Co. common stock in multiple transactions on June 20, 2024, at weighted average prices ranging from $902.253 to $904.245.

Gabrielle Sulzberger, a director at Eli Lilly & Co, acquired 11 shares of common stock through a deferral plan.